

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow[®], innovative solution dedicated to oncology imaging

Villepinte, Montpellier, Villejuif, Angers, December 3, 2024 at 5:45 PM CET

Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian[®] and Liflow[®], Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance's "Innovation in Medical Imaging" call for proposals. The Oncology Assistant (trade name: Liflow[®]) project, carried by the four Partners uses AI (artificial intelligence) to facilitate and optimize the follow-up of cancer patients. It benefits from public funding to ensure its future development.

Supporting innovation in medical imaging

The "Innovation in Medical Imaging" call for proposals launched in 2023 by Bpifrance as part of its "Digital Health" acceleration strategy aims to stimulate the development and the structuring of a medical imaging branch of excellence in France, by supporting innovative and high-potential companies.

Guerbet, Intrasense, the Gustave Roussy Institute and Angers University Hospital joined forces in a unique consortium to participate in this call for proposals together. The Partners presented the Oncology Assistant project, with a dedicated imaging solution for oncology follow-up enhanced by artificial intelligence algorithms (Liflow[®]).

Selected from many French submissions presented in September 2023, the project carried by the Partners differentiates itself by its innovative aspect in the digital and health sectors. With growing numbers of cancer cases worldwide and a need for increased accuracy for imaging professionals, the development of an oncology follow-up software solution, natively embedding several AI algorithms dedicated to multiple organs, will change clinical practice. By providing access to oncology follow-up innovative indicators such as automated calculation and measurement of the tumour load, the project also has a goal to improve patients follow-up. This innovative indicator will enable medical teams to optimize treatments¹.

The project aims to contribute to the development of a CT-TAP (thorax-abdomen-pelvis) analysis solution in clinical routine to gain diagnosis accuracy and significantly improve cancer patients care.

¹ Lama Dawi, Younes Belkouchi, Littisha Lawrance, Othilie Gautier • Samy Ammari, ... & Nathalie Lassau, (2024) - Liquid Biopsy versus CT: Comparison of Tumor Burden - Quantification in 1065 Patients with Metastases. Radiology 2024; 313(2):e232674.

"The financial support of Bpifrance will allow us to accelerate the development of a major innovative solution for oncology imaging follow-up. By relying on multi-organ AIs our platform will enable radiologists to simultaneously detect and follow-up lesions in all organs. In collaboration with our academic partners, we will demonstrate how this progress offers a beneficial and significant efficiency gain for oncology imaging professionals and patients." says **François Nicolas**, Vice President in charge of R&D at Guerbet and Chairman of the Board of Intrasense, a group subsidiary.

Funding for oncology imaging

As part of the global €5.9M financial package awarded to the Partners by Bpifrance, Guerbet, project leader, received €1.9M to develop a foundational AI model enabling lesion detection and follow-up in the main organs (lung, liver, bones, lymph nodes, peritoneum, kidneys, pancreas). These AIs will meet the growing needs for automation and efficiency in oncology imaging.

Intrasense, with a €1.7M financial help will ensure the application development of Liflow® solution integrating Guerbet's AIs in an optimized workflow. Intrasense will carry the regulatory certification of the solution and of the artificial intelligence algorithms. The funding allocated to the project will enable to overcome technological and clinical hurdles, and thus accelerate the development of Liflow®.

Angers University Hospital and the Gustave Roussy Institute with fundings of €0.9M and €1.4M, will bring a scientific and clinical expertise to every step of the project. They will play a crucial role in medical support developing products, ensuring that every innovation meets radiologists' clinical needs.

Bpifrance's support will allow us to carry on several clinical studies aiming to demonstrate the impact and the efficiency of new technologies on daily clinical practice. The main objective is to provide healthcare professionals with tools allowing a faster evaluation of the patients' response (or non-response) to treatments, leading to a therapeutic optimization and improved care.

"Our research in tumour load imaging and anthropometrics at the Gustave Roussy Institute, conducted for several years now, convinced us of the importance of integrating these prognosis and predictive biomarkers in patient care¹. This project, to term, will enable its use in a clinical routine workflow", says **Pr Nathalie Lassau**, university professor and hospital practitioner at Paris-Saclay University in radiology, radiologist at Gustave Roussy Institute.

"To integrate AI into the care process, we needed to create a tool that was not single-tasked but that assisted radiologists in their complex work of interpretation. The analysis of CT-TAP in oncology is time-consuming and tedious; Liflow® should reduce the time needed for interpretation and improve performance. It will be a major change", says **Pr Christophe Aubé**, university professor and hospital practitioner, Head of the radiology department at Angers University Hospital.

¹ Lama Dawi, Younes Belkouchi, Littisha Lawrance, Othilie Gautier • Samy Ammari, ... & Nathalie Lassau, (2024) - Liquid Biopsy versus CT: Comparison of Tumor Burden - Quantification in 1065 Patients with Metastases. Radiology 2024; 313(2):e232674.

A project punctuated by regular milestones over five years

The first year of the project will be dedicated to developing Liflow® platform and the overall innovative functionalities: oncology exam analysis automation by anatomical area, facilitated access to multi-organ AIs results, automated calculation of tumour evolution. From 1st half 2025, an advanced version of the platform will be revealed, integrating three applications based on artificial intelligence. Among them, two are specifically developed by Guerbet to offer a precise analysis and help in reviewing liver, bones, and lung lesions. To do so, a data base of over 100.000 3D segmented lesions was built and will continue to be fed to reach 250.000 lesions in 2025.

During the five years of the Oncology Assistant project, Liflow® application will continue to be enhanced by the gradual addition of new applications based on artificial intelligence. These innovations will cover a large panel of organs and biomarkers, enabling the anticipation of future needs in terms of diagnosis, follow-up and treatment of cancer patients.

"We thank Bpifrance for their trust and this financial support that demonstrate the quality of our innovations for health. This funding will allow us to accelerate the development of our solution and to add differentiating major elements to optimize oncology imaging analysis and follow-up. This ambitious project, led by a unique consortium made by prestigious actors, will enable us to develop a major innovation for oncology imaging follow-up. Together we are willing to take on new challenges" adds **Alexandre Salvador, CEO of Intrasense.**

About Guerbet

At Guerbet, we build lasting relationships to help people live better. This is our raison d'être. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices and digital and AI solutions for diagnostic and interventional imaging. A pioneer for 95 years in the field of contrast media, with more than 2,830 employees worldwide, we are constantly

innovating and devote 10% of our sales to Research & Development in four centers in France, Israel and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and achieved a turnover of €786 million in 2023.

For further information, please visit www.guerbet.com.

Guerbet

Christine Allard
Head of Public Affairs and Communications
Phone: +33 6 30 11 57 82

christine.allard@guerbet.com

About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian^{®2}, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow^{®2}, a new

platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up. A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense

Salomé Sylvestre
Communications Officer
Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean
Financial Communication
and investor relations
Phone: +331 44 71 20 40

intrasense@newcap.eu

About Gustave Roussy

Ranked number one in France, number one in Europe and number four worldwide, Gustave Roussy is a global centre of expertise entirely dedicated to patients living with cancer.

The Institute is a founding pillar of the Paris-Saclay Cancer Cluster. A source of therapeutic innovation and diagnostic breakthroughs, the Institute cares for almost 50,000 patients every year, including 3,500 children and adolescents, and is developing an integrated approach to research, care and teaching.

An expert in rare and complex cancers, Gustave Roussy treats all cancers, at all stages of life. It offers its patients

personalized care that combines innovation and humanity, taking into account not only treatment but also physical, psychological and social quality of life. With 4,300 employees on two sites, Villejuif and Chevilly-Larue, Gustave Roussy combines the expertise essential for top-level cancer research; 40% of patients treated are included in clinical trials.

To find out more about Gustave Roussy and keep up to date with news from the Institute:

www.gustaveroussy.fr, Twitter, Facebook, LinkedIn, Instagram.

Gustave Roussy

Claire Parisel
Responsable des relations médias
Tél. : +336 17 66 00 26

claire.parisel@gustaveroussy.fr

² Myrian[®] and Liflow[®] are medical devices carrying the CE marking

About Angers University Hospital

Angers University Hospital is a leading healthcare center with a four-fold mission: care, teaching, research and prevention. Both a local healthcare establishment and a center for referral and expertise, it combines innovation and solidarity on a daily basis. With 9 departments and 60 clinical and biological services, the UHC's healthcare offer covers all medical, surgical and biological specialties, including oncology, and a medico-social service for residents. The most complex or rare specialties are cared for by 53 reference, resource and competence centers. Patients are cared for by university hospital teams whose performance is supported by state-of-the-art technical facilities.

As one of the region's leading healthcare operators, with 210,775 patients a year and 1,751 beds and places, including 410 beds in the medical-social sector, Angers UHC places patient service at the forefront of its quality drive. As a member of HUGO (GSC Hôpitaux Universitaires

du Grand Ouest), Angers University Hospital also coordinates a research cluster within the hospital and in the region through the DRCIT (Direction à la Recherche Clinique et à l'Innovation Territoriale), as well as higher education.

With 7,106 employees, it is the largest employer in the city and one of the largest in the Pays de la Loire region and is also involved in the training of future healthcare professionals through the training of doctors and nurses. A position that makes the UHC a factor of social cohesion and one of the leading partners of other public and private health establishments in the region.

Find out more about Angers University Hospital: www.chu-angers.fr, Facebook, LinkedIn, Twitter, Instagram.

CHU d'Angers

Marie Caron
Patients Attractivity Director
Cabinet and Communication Director
Phone: +332 41 35 33 34

marie.caron@chu-angers.fr

CHU d'Angers

Kelly Huyghe
Communication Manager
Phone: +33 41 35 77 05

kelly.huyghe@chu-angers.fr